Sign In
Buy DGX
$196.12
+2.45 (+1.27%)
At Close: Jun 04, 2026
Encompass Health (EHC) Down 6.4% Since Last Earnings Report: Can It Rebound?
05:31pm, Friday, 27'th May 2022 Zacks Investment Research
Encompass Health (EHC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why at-home COVID-19 tests may limit the way the U.S. tracks new cases
12:03pm, Monday, 16'th May 2022 MarketWatch
The majority of people in the U.S. who are testing positive for the virus right now likely aren’t being included in official case counts.
Quest Diagnostics to Speak at the UBS 2022 Global Healthcare Conference
01:40pm, Wednesday, 11'th May 2022
SECAUCUS, N.J. , May 11, 2022 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it is scheduled to speak at t
7 Defensive Dividend Healthcare Stocks to Buy Now
07:33am, Friday, 06'th May 2022
As market conditions remain rocky, adding high-quality healthcare stocks to your portfolio may be a great way to play defense. The post 7 Defensive Dividend Healthcare Stocks to Buy Now appeared first
Here's Why You Should Retain Quest Diagnostics (DGX) Stock Now
01:30pm, Tuesday, 03'rd May 2022 Zacks Investment Research
Investors are optimistic about Quest Diagnostics (DGX) owing to a strong recovery in base business and raised 2022 outlook.
Here's Why You Should Retain Quest Diagnostics (DGX) Stock Now
10:32am, Tuesday, 03'rd May 2022
Investors are optimistic about Quest Diagnostics (DGX) owing to a strong recovery in base business and raised 2022 outlook.
Analyst Ratings for Quest Diagnostics
01:10pm, Friday, 22'nd Apr 2022 Benzinga
Quest Diagnostics (NYSE:DGX) has observed the following analyst ratings within the last quarter:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
1
0
5
0
0
Last 3
CDC says face masks are still needed to protect the public, and WHO says omicron accounts for 99.5% of global COVID cases
10:30am, Friday, 22'nd Apr 2022 MarketWatch
The Justice Department has filed an appeal seeking to overturn a federal judge's ruling that ended the face-mask mandate on planes and other modes of public transportation, after the Centers for Disea
Quest Diagnostics Incorporated's (DGX) CEO Steve Rusckowski on Q1 2022 Results - Earnings Call Transcript
02:02pm, Thursday, 21'st Apr 2022
Quest Diagnostics Incorporated (NYSE:DGX ) Q1 2022 Earnings Conference Call April 21, 2022 8:30 AM ET Company Participants Shawn Bevec - Vice President, Investor Relations Steve Rusckowski - Chairman
Quest Diagnostics (DGX) Beats Q1 Earnings Estimates
12:15pm, Thursday, 21'st Apr 2022 Zacks Investment Research
Quest Diagnostics (DGX) delivered earnings and revenue surprises of 10.65% and 1.02%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Quest Diagnostics (DGX) Beats Q1 Earnings Estimates
09:47am, Thursday, 21'st Apr 2022
Quest Diagnostics (DGX) delivered earnings and revenue surprises of 10.65% and 1.02%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Should You Buy Quest Diagnostics (DGX) Ahead of Earnings?
12:42pm, Tuesday, 19'th Apr 2022 Zacks Investment Research
Quest Diagnostics (DGX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Should You Buy Quest Diagnostics (DGX) Ahead of Earnings?
09:47am, Tuesday, 19'th Apr 2022
Quest Diagnostics (DGX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Quest Diagnostics (DGX) Q1 Earnings to Grow on Base Business
01:03pm, Monday, 18'th Apr 2022 Zacks Investment Research
Quest Diagnostics (DGX) is expected to report a strong first half of Q1 with a growing number of cases and then a dull second half on gradual stabilization in testing demand.
Quest Diagnostics (DGX) Q1 Earnings to Grow on Base Business
10:32am, Monday, 18'th Apr 2022
Quest Diagnostics (DGX) is expected to report a strong first half of Q1 with a growing number of cases and then a dull second half on gradual stabilization in testing demand.
